New malaria vaccine trial aims to block infection without causing illness
NCT ID NCT06862453
First seen Jan 15, 2026 · Last updated Jun 06, 2026 · Updated 22 times
Summary
This early-stage trial tests a new malaria vaccine (PfSPZ-LARC2) in 58 healthy adults who have never had malaria. The vaccine uses weakened malaria parasites that stop growing in the liver and cannot cause blood infection. Researchers will check if it is safe and if it protects against malaria when volunteers are later exposed to the parasite.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA, FALCIPARUM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Tubingen
RECRUITINGTübingen, D-72074, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.